NCT04948333 2026-03-18Asciminib Treatment Optimization in ≥ 3rd Line CML-CPNovartisPhase 3 Completed199 enrolled 13 charts
NCT04820023 2025-06-06Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI TreatmentBridge Biotherapeutics, Inc.Phase 1/2 Terminated45 enrolled 19 charts